Shire Plc American Depositary Shares (SHPG) 255.11 $SHPG
Big Pharma Comes Under Attack From a New Hedge Fund Strategy
Sean Williams, The Motley Fool - Motley Fool - Sun Apr 26, 10:04AM CDT
Source: Teva Pharmaceutical, Facebook. Forget retail short-sellers and angry message board posters, Big Pharma has a much bigger concern on the horizon: hedge funds. I know what you're probably thinking, "Haven't various hedge funds already been...
ACT: 295.41 (-2.95), SHPG: 255.11 (-0.26), PFE: 35.27 (-0.09), JAZZ: 189.42 (+0.33), TEVA: 64.41 (+1.16)
Novartis (NVS) Beats on Earnings in Q1, View Reiterated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 9:00AM CDT
Novartis' core earnings earnings per share came in at $1.33, down from $1.35 in the year-ago period but above the Zacks Consensus Estimate of $1.09.
SHPG: 255.11 (-0.26), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22)
Pfizer's Once And Future Deals
Chris DeMuth Jr. - at Seeking Alpha - Thu Apr 23, 2:39PM CDT
SHAK: 68.53 (+5.80), GS: 197.99 (-1.32), MDT: 77.61 (-0.89), JPM: 62.60 (-0.20), SHPG: 255.11 (-0.26), COV: 106.71 (-1.36), PFE: 35.27 (-0.09), AZN: 71.79 (-1.34), BAC: 15.64 (-0.05), ABBV: 66.07 (+1.82), HSP: 87.61 (-0.05), MS: 37.36 (-0.02)
AbbVie Beats Earnings on Humira and HCV Sales, Ups View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Apr 23, 10:18AM CDT
AbbVie (ABBV) surpassed expectations on the back of Humira sales and contribution from Viekira.
BIIB: 401.71 (-28.57), PCYC: 256.59 (-0.51), SHPG: 255.11 (-0.26), ABBV: 66.07 (+1.82)
AbbVie raises outlook as Humira again delivers earnings beat
By MATTHEW PERRONE - AP - Thu Apr 23, 9:48AM CDT
WASHINGTON (AP) — Drugmaker AbbVie is raising its full-year earnings guidance after reporting better-than-expected first quarter adjusted results on continued growth of its blockbuster anti-inflammatory drug Humira.
JNJ: 101.08 (+0.62), SHPG: 255.11 (-0.26), AMGN: 167.91 (-1.26)
Arris Group to Acquire U.K.'s Pace to Expand, Save on Taxes
at The Street - Thu Apr 23, 9:47AM CDT
Arris is expanding its video services.
NFLX: 558.40 (-0.66), ARRS: 35.76 (-1.54), SHPG: 255.11 (-0.26), GOOGL: 573.66 (+16.20), ABBV: 66.07 (+1.82), CYBX: 62.89 (-0.30)
Roche Beats on Q1 Sales driven by Oncology & Immunology - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 9:18AM CDT
Roche Holding AG's (RHHBY) performance in the first quarter was impressive. The oncology portfolio looks solid as ever and we expect further traction in 2015 from the HER2 franchise.
VRX: 210.42 (+1.03), SHPG: 255.11 (-0.26)
Hedge fund honcho eyes Biogen patent covering top-selling Tecfidera
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 3:04PM CDT
BIIB: 401.71 (-28.57), SHPG: 255.11 (-0.26), ACOR: 33.12 (-0.38)
Abbott Labs (ABT) Beats on Q1 Earnings, View Reiterated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 12:18PM CDT
Abbott Laboratories (ABT) reported first-quarter 2015 earnings of 47 cents per share, up 38.2% from the year-ago quarter and beat the Zacks Consensus Estimate of 42 cents.
ABT: 48.32 (-0.14), VRX: 210.42 (+1.03), SHPG: 255.11 (-0.26), MYL: 76.06 (+2.37)
3 Large-Cap Pharmaceutical Companies to Invest in Right Now
at The Street - Wed Apr 22, 8:23AM CDT
Pharmaceutical companies can be a huge risk for investors -- but if the risks pay off, the rewards can be huge.
NVO: 56.65 (+0.44), SHPG: 255.11 (-0.26), RDY: 55.55 (-0.83)
Gilead Sciences Vs. AbbVie: Which Is A Better Buy?
Mycroft - at Seeking Alpha - Wed Apr 22, 7:49AM CDT
JNJ: 101.08 (+0.62), ABT: 48.32 (-0.14), PCYC: 256.59 (-0.51), GILD: 103.69 (-1.52), SHPG: 255.11 (-0.26), ABBV: 66.07 (+1.82)
Seattle Genetics' Adcetris Under Review for New Indication - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 5:07PM CDT
Seattle Genetics, Inc.'s (SGEN) supplemental BLA for Adcetris has been accepted by the FDA for priority review as consolidation therapy in the post-transplant setting.
SGEN: 37.14 (-0.36), SHPG: 255.11 (-0.26), HZNP: 31.75 (+0.97), BMY: 65.80 (-0.20)
Merck KGaA-Pfizer Start First Cancer Registration Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:50PM CDT
Merck KGaA (MKGAF) and Pfizer Inc. (PFE) announced the commencement of a phase III study on avelumab in comparison with Taxotere for non-small cell lung cancer.
SHPG: 255.11 (-0.26), PFE: 35.27 (-0.09), HZNP: 31.75 (+0.97)
Ampio Plunges as STRIDE Study on Ampion Fails - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 11:48AM CDT
Ampio Pharmaceuticals, Inc. (AMPE) announced disappointing results from the multiple injection STRIDE study AP008 on pipeline candidate Ampion.
VRX: 210.42 (+1.03), SHPG: 255.11 (-0.26), ARQL: 2.12 (unch), AMPE: 2.73 (-0.16)
Genzyme starts mid-stage trial of oral Fabry disease therapy
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 10:34AM CDT
SHPG: 255.11 (-0.26), PLX: 2.23 (+0.01), SNY: 51.75 (-0.01), FOLD: 12.25 (-0.05)
Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019
M2 - Mon Apr 20, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w97ksb/global_acquired) has announced the addition of the "Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019" report to their offering. The Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29% over the period 2014-2019 Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS. Entry into untapped markets is one of the major trends upcoming in the market. Currently, the market in many geographical locations remains untapped and provides immense opportunities for vendors to invest in the same. Companies that are pioneers in the development of drugs for acquired orphan blood diseases target physicians who prescribe patients these drugs instead of surgeries and chemotherapy. This has helped manufacturers to increase their product price. According to the report, patients diagnosed with acquired orphan blood diseases mostly rely on generics for the treatment. Side effects of these drugs are high and the treatment regimen requires high level of commitment from patients such as regular hospital visits and checkups. Further, the report states that most pharmaceutical and biotech companies invest extensively in the development of novel drugs to treat rare diseases. However, when marketing and distribution of drugs to potential consumers is taken into consideration, companies are hesitant to invest for the same. Low prevalence of orphan diseases makes it difficult for companies to locate the target population. Key Vendors - Alexion Pharmaceuticals - Amgen - Celgene - F. Hoffmann- La Roche - GlaxoSmithKline - Incyte Other Prominent Vendors - Cyclacel Pharmaceuticals - CTI Biopharma (Cell Therapeutics) - Eli Lilly - Gilead Sciences - Onconova Therapeutics - MebVax Therapeutics - Novartis - Sanofi - Shire Pharmaceuticals - S* Bio Pte For more information visit http://www.researchandmarkets.com/research/w9...l_acquired
CYCC: 0.96 (+0.02), GILD: 103.69 (-1.52), SHPG: 255.11 (-0.26), ALXN: 180.08 (-4.50), AMGN: 167.91 (-1.26), ONTX: 2.34 (-0.05), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22), CELGZ: 2.76 (-0.12)
This New Hedge Fund Strategy Just Might Be Crazy Enough To Work
Matthew Frankel, The Motley Fool - Motley Fool - Sun Apr 19, 1:07PM CDT
Hedge funds use a lot of strategies to make money, but one manager is doing something we've never seen before in order to make a profit -- challenging a company's patents and shorting its stock simultaneously. How exactly does it work, and will it...
SHPG: 255.11 (-0.26), JAZZ: 189.42 (+0.33), ACOR: 33.12 (-0.38)
Will This Hedge Fund Manager Bring Down Your Biotech Stocks?
Selena Maranjian, The Motley Fool - Motley Fool - Sun Apr 19, 12:01PM CDT
Hedge-fund manager Kyle Bass. Image: Insider Monkey Many hedge-fund managers are "activist" ones. They load up on stock in particular companies until they have so many shares that they can put pressure on management to take actions they...
SHPG: 255.11 (-0.26), JAZZ: 189.42 (+0.33), ACOR: 33.12 (-0.38)
Big Pharma Comes Under Attack From a New Hedge Fund Strategy
Sean Williams, The Motley Fool - Motley Fool - Sun Apr 26, 10:04AM CDT
Source: Teva Pharmaceutical, Facebook. Forget retail short-sellers and angry message board posters, Big Pharma has a much bigger concern on the horizon: hedge funds. I know what you're probably thinking, "Haven't various hedge funds already been...
ACT: 295.41 (-2.95), SHPG: 255.11 (-0.26), PFE: 35.27 (-0.09), JAZZ: 189.42 (+0.33), TEVA: 64.41 (+1.16)
Novartis (NVS) Beats on Earnings in Q1, View Reiterated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 9:00AM CDT
Novartis' core earnings earnings per share came in at $1.33, down from $1.35 in the year-ago period but above the Zacks Consensus Estimate of $1.09.
SHPG: 255.11 (-0.26), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22)
Pfizer's Once And Future Deals
Chris DeMuth Jr. - at Seeking Alpha - Thu Apr 23, 2:39PM CDT
SHAK: 68.53 (+5.80), GS: 197.99 (-1.32), MDT: 77.61 (-0.89), JPM: 62.60 (-0.20), SHPG: 255.11 (-0.26), COV: 106.71 (-1.36), PFE: 35.27 (-0.09), AZN: 71.79 (-1.34), BAC: 15.64 (-0.05), ABBV: 66.07 (+1.82), HSP: 87.61 (-0.05), MS: 37.36 (-0.02)
AbbVie Beats Earnings on Humira and HCV Sales, Ups View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Apr 23, 10:18AM CDT
AbbVie (ABBV) surpassed expectations on the back of Humira sales and contribution from Viekira.
BIIB: 401.71 (-28.57), PCYC: 256.59 (-0.51), SHPG: 255.11 (-0.26), ABBV: 66.07 (+1.82)
AbbVie raises outlook as Humira again delivers earnings beat
By MATTHEW PERRONE - AP - Thu Apr 23, 9:48AM CDT
WASHINGTON (AP) — Drugmaker AbbVie is raising its full-year earnings guidance after reporting better-than-expected first quarter adjusted results on continued growth of its blockbuster anti-inflammatory drug Humira.
JNJ: 101.08 (+0.62), SHPG: 255.11 (-0.26), AMGN: 167.91 (-1.26)
Arris Group to Acquire U.K.'s Pace to Expand, Save on Taxes
at The Street - Thu Apr 23, 9:47AM CDT
Arris is expanding its video services.
NFLX: 558.40 (-0.66), ARRS: 35.76 (-1.54), SHPG: 255.11 (-0.26), GOOGL: 573.66 (+16.20), ABBV: 66.07 (+1.82), CYBX: 62.89 (-0.30)
Roche Beats on Q1 Sales driven by Oncology & Immunology - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 9:18AM CDT
Roche Holding AG's (RHHBY) performance in the first quarter was impressive. The oncology portfolio looks solid as ever and we expect further traction in 2015 from the HER2 franchise.
VRX: 210.42 (+1.03), SHPG: 255.11 (-0.26)
Hedge fund honcho eyes Biogen patent covering top-selling Tecfidera
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 3:04PM CDT
BIIB: 401.71 (-28.57), SHPG: 255.11 (-0.26), ACOR: 33.12 (-0.38)
Abbott Labs (ABT) Beats on Q1 Earnings, View Reiterated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 12:18PM CDT
Abbott Laboratories (ABT) reported first-quarter 2015 earnings of 47 cents per share, up 38.2% from the year-ago quarter and beat the Zacks Consensus Estimate of 42 cents.
ABT: 48.32 (-0.14), VRX: 210.42 (+1.03), SHPG: 255.11 (-0.26), MYL: 76.06 (+2.37)
3 Large-Cap Pharmaceutical Companies to Invest in Right Now
at The Street - Wed Apr 22, 8:23AM CDT
Pharmaceutical companies can be a huge risk for investors -- but if the risks pay off, the rewards can be huge.
NVO: 56.65 (+0.44), SHPG: 255.11 (-0.26), RDY: 55.55 (-0.83)
Gilead Sciences Vs. AbbVie: Which Is A Better Buy?
Mycroft - at Seeking Alpha - Wed Apr 22, 7:49AM CDT
JNJ: 101.08 (+0.62), ABT: 48.32 (-0.14), PCYC: 256.59 (-0.51), GILD: 103.69 (-1.52), SHPG: 255.11 (-0.26), ABBV: 66.07 (+1.82)
Seattle Genetics' Adcetris Under Review for New Indication - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 5:07PM CDT
Seattle Genetics, Inc.'s (SGEN) supplemental BLA for Adcetris has been accepted by the FDA for priority review as consolidation therapy in the post-transplant setting.
SGEN: 37.14 (-0.36), SHPG: 255.11 (-0.26), HZNP: 31.75 (+0.97), BMY: 65.80 (-0.20)
Merck KGaA-Pfizer Start First Cancer Registration Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:50PM CDT
Merck KGaA (MKGAF) and Pfizer Inc. (PFE) announced the commencement of a phase III study on avelumab in comparison with Taxotere for non-small cell lung cancer.
SHPG: 255.11 (-0.26), PFE: 35.27 (-0.09), HZNP: 31.75 (+0.97)
Ampio Plunges as STRIDE Study on Ampion Fails - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 11:48AM CDT
Ampio Pharmaceuticals, Inc. (AMPE) announced disappointing results from the multiple injection STRIDE study AP008 on pipeline candidate Ampion.
VRX: 210.42 (+1.03), SHPG: 255.11 (-0.26), ARQL: 2.12 (unch), AMPE: 2.73 (-0.16)
Genzyme starts mid-stage trial of oral Fabry disease therapy
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 10:34AM CDT
SHPG: 255.11 (-0.26), PLX: 2.23 (+0.01), SNY: 51.75 (-0.01), FOLD: 12.25 (-0.05)
Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019
M2 - Mon Apr 20, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w97ksb/global_acquired) has announced the addition of the "Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019" report to their offering. The Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29% over the period 2014-2019 Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS. Entry into untapped markets is one of the major trends upcoming in the market. Currently, the market in many geographical locations remains untapped and provides immense opportunities for vendors to invest in the same. Companies that are pioneers in the development of drugs for acquired orphan blood diseases target physicians who prescribe patients these drugs instead of surgeries and chemotherapy. This has helped manufacturers to increase their product price. According to the report, patients diagnosed with acquired orphan blood diseases mostly rely on generics for the treatment. Side effects of these drugs are high and the treatment regimen requires high level of commitment from patients such as regular hospital visits and checkups. Further, the report states that most pharmaceutical and biotech companies invest extensively in the development of novel drugs to treat rare diseases. However, when marketing and distribution of drugs to potential consumers is taken into consideration, companies are hesitant to invest for the same. Low prevalence of orphan diseases makes it difficult for companies to locate the target population. Key Vendors - Alexion Pharmaceuticals - Amgen - Celgene - F. Hoffmann- La Roche - GlaxoSmithKline - Incyte Other Prominent Vendors - Cyclacel Pharmaceuticals - CTI Biopharma (Cell Therapeutics) - Eli Lilly - Gilead Sciences - Onconova Therapeutics - MebVax Therapeutics - Novartis - Sanofi - Shire Pharmaceuticals - S* Bio Pte For more information visit http://www.researchandmarkets.com/research/w9...l_acquired
CYCC: 0.96 (+0.02), GILD: 103.69 (-1.52), SHPG: 255.11 (-0.26), ALXN: 180.08 (-4.50), AMGN: 167.91 (-1.26), ONTX: 2.34 (-0.05), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22), CELGZ: 2.76 (-0.12)
This New Hedge Fund Strategy Just Might Be Crazy Enough To Work
Matthew Frankel, The Motley Fool - Motley Fool - Sun Apr 19, 1:07PM CDT
Hedge funds use a lot of strategies to make money, but one manager is doing something we've never seen before in order to make a profit -- challenging a company's patents and shorting its stock simultaneously. How exactly does it work, and will it...
SHPG: 255.11 (-0.26), JAZZ: 189.42 (+0.33), ACOR: 33.12 (-0.38)
Will This Hedge Fund Manager Bring Down Your Biotech Stocks?
Selena Maranjian, The Motley Fool - Motley Fool - Sun Apr 19, 12:01PM CDT
Hedge-fund manager Kyle Bass. Image: Insider Monkey Many hedge-fund managers are "activist" ones. They load up on stock in particular companies until they have so many shares that they can put pressure on management to take actions they...
SHPG: 255.11 (-0.26), JAZZ: 189.42 (+0.33), ACOR: 33.12 (-0.38)
